Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study

Eitemau Tebyg

• Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
  gan: Alam, Mohammed Y., et al.
  Cyhoeddwyd: (2014)
• The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
  gan: Baldwin, David S, et al.
  Cyhoeddwyd: (2016)
• A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder
  gan: Mahableshwarkar, Atul R, et al.
  Cyhoeddwyd: (2015)
• A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder
  gan: Mahableshwarkar, Atul R, et al.
  Cyhoeddwyd: (2016)
• Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study
  gan: Peters-Strickland, Timothy, et al.
  Cyhoeddwyd: (2015)